MedTrace Logo

A Study to Assess the Efficacy and Safety of ABTL0812

NCT03366480 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2023-02-22

No results posted yet for this study

Summary

A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.

Conditions

Interventions

DRUG

ABTL0812 in combination with paclitaxel and carboplatin

ABTL0812 in combination with paclitaxel and carboplatin.

Sponsors & Collaborators

  • Hospital Vall d'Hebron

    collaborator OTHER

  • Institut Català d'Oncologia

    collaborator OTHER

  • Hospital Clínico Universitario de Valencia

    collaborator OTHER

  • Hospitales Universitarios Virgen del Rocío

    collaborator OTHER

  • Centre Leon Berard

    collaborator OTHER

  • Institut Paoli-Calmettes

    collaborator OTHER

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • Ability Pharmaceuticals SL

    lead INDUSTRY

Principal Investigators

  • Ana Oaknin · VHIO

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2020-06-01
Completion
2020-11-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366480 on ClinicalTrials.gov